NCT07762495Not yet recruitingEarly phase 1
Echocardiographic Molecular Imaging for POC Detection of Ischemia
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
Molecular imaging with myocardial contrast echocardiography (MCE) relies on the non-invasive detection of targeted microbubbles (MBs) or other acoustically active agents. The confinement of MBs to the vascular compartment makes them ideal for assessing acute inflammatory responses involving endothelial cell activation and immune cell recruitment. A construct for imaging inflammation and endothelial activation can be achieved by altering amphipathic lipid shell composition in MBs. Specifically, incorporation of phosphatidylserine (PS) into the shell of MBs promotes adhesion to activated leukocytes and endothelial cells which can be used to detect ischemia, whether active or resolved. Our first in human studies to use myocardial contrast echocardiography (MCE) to detect inflammation secondary to ischemia was performed with a PS-containing MB contrast agent (Sonazoid) where we studied patients with known acute coronary syndrome (ACS) who had just undergone acute percutaneous coronary intervention. In this study, we will conduct a proof-of-concept clinical trial where MCE molecular imaging with Sonazoid will be performed in 80 patients with suspected rather than known ACS. We will test whether MCE ischemic memory imaging with MB-PS can diagnose or exclude ACS, and assess risk based on spatial extent of signal enhancement.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 8 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Jun 2030
- Lead sponsor
- University of Virginia
- Diseases
- Coronary artery disease
- NCT number
- NCT07762495
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 80
- From Sept 2026 to the primary completion date, Jun 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe heart failure (NYHA class IV)
- Ongoing life-threatening arrhythmias
- Allergy to ultrasound contrast agents or eggs
- History of autoimmune or inflammatory disease with myocardial involvement (SLE, sarcoidosis, giant cell myocarditis, etc.)
Other
- Cardiogenic shock
- Inability to obtain consent
- Mechanical complication of MI (ischemic VSD, papillary muscle rupture, ventricular free wall rupture)
- Neutropenia (\<1,500/mm3)
- Pregnancy
- Lactation
Who the study is looking for
- Age ≥18 years of age
- Patients with possible or suspected ACS based on clinical criteria (history, ECG, laboratories) and HEART score \>3.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.